Search by Journal
- HOME
- > Search by Journal
- > Pharmacometrics
Pharmacometrics
Volume 90, Issue 5/6 / 2016
English Article Japanese Article
- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
The Effect of Intake of Gliadin-Combined Superoxide Dismutase (SOD)-rich Melon Extract (GME) on Minimal Erythema Dose (MED) : A Randomised, Double-blind, Placebo-controlled, Parallel-group Study of Healthy Japanese. Shu Takayanagi, Hiromasa Suzuki, Miki Yokozawa, Ken Yamauchi Pharmacometrics 90(5/6): 77-81, 2016. |
Hydrophilia, Tablet Strength, and Pushing Out by Pressing Through the Package of Acarbose and Rebamipide Orally Disintegrating Tablets Sumio Chono, Momoka Kawada, Yuri Takada Pharmacometrics 90(5/6): 83-85, 2016. |
Effect of Soybean β-Conglycinin on Serum Triglyceride Mitsutaka Kohno1), Motohiko Hirotsuka2) Pharmacometrics 90(5/6): 87-93, 2016. |
Combined Effect of Lysed Enterococcus faecalis FK-23 and Fruits of Citrus unshiu on Contact Dermatitis in Mice Kyohei Nishikawa1), Takashi Shimada1,2), Atsushi Hayashi1), Mariko Okamori1), Kazutake Fukada1), Akiko Goshima1), Kimihisa Itoh3), Kazuya Murata4), Hideaki Matsuda3,4) Pharmacometrics 90(5/6): 95-99, 2016. |
Oral Intake of Collagen Peptide Improves Skin Condition Miho Miyanaga, Taro Uchiyama, Osamu Ueda Pharmacometrics 90(5/6): 101-107, 2016. |
Study on the Preventive and Therapeutic Effects of L-cysteine on Pigmentation Using a Guinea Pig Sunburn Model Yasushi Yamada1), Ikuko Asano1), Atsushi Sawamura2), Nobuo Miyadai2), Ichiro Kawase2) Pharmacometrics 90(5/6): 109-115, 2016. |
Emotion and mnemonic control to think about from the signal in SL1 cells 貝淵弘三 Pharmacometrics 90(5/6): 120-120, 2016. |
Activation of the nerve trunk cells with the SL2 green tea amino acid 米田幸雄 Pharmacometrics 90(5/6): 121-121, 2016. |
The translational research which assumed fundamental researches result of child Shati/Nat81 the cause for S1-1 newcomer 新田淳美 Pharmacometrics 90(5/6): 124-124, 2016. |
About the effect of dipeptide Leu-Ile on S1-2 cranial nerve disease 日比陽子1, アルカムトルソン1, 鍋島俊隆2,3, 新田淳美4 Pharmacometrics 90(5/6): 125-125, 2016. |
A functional analysis and the clinical application of the S1-3 nerve mental disorder-related factor: Approach from the basics, clinical studies 野田幸裕, 肥田裕丈, 吉見陽 Pharmacometrics 90(5/6): 126-126, 2016. |
Mental disorder onset prophylactic efforts judging from S1-4 dietetics 橋本謙二 Pharmacometrics 90(5/6): 127-127, 2016. |
About effect to give the bone metabolism of the S2-1 new antiepileptic drug (E Keppra) 小野寺憲治1,2, 若林広行3, 神田循吉3, 曾我孝志1 Pharmacometrics 90(5/6): 128-128, 2016. |
S2-2 BMP signal and bone metabolism 檜井栄一 Pharmacometrics 90(5/6): 129-129, 2016. |
Bone metabolism control due to the S2-3 sympathetic nerve 平居貴生, 戸苅彰史 Pharmacometrics 90(5/6): 130-130, 2016. |
Skin function improvement effect of glucosylceramide derived from S3-1 beauty food pineapple 川本広明1, 野嶋潤1, 吉野進1, 岩崎大剛1, 三宅康夫1, 大戸信明1, 西谷洋輔1, 桑原浩誠1, 水野雅史2 Pharmacometrics 90(5/6): 131-131, 2016. |
The intestinal tract inflammation inhibitory effect of the S3-2 Lactobacillus plantarum 22A-3 strain and the mechanism of action 水野雅史1, 中村冬馬2, 林多恵子2, 西谷洋輔2, 大戸信明2, 三宅康夫2, 桑原浩誠2 Pharmacometrics 90(5/6): 132-132, 2016. |
Effect expression mechanism of the black ginger with the S3-3 antiobese effect 森田敏宏1, 吉野進2, 阿波里佳2, 三宅康夫2, 大戸信明2, 桑原浩誠2 Pharmacometrics 90(5/6): 133-133, 2016. |
S4-1 Survey of natural resources with pharmacological activities and their application to functional foods or natural medicines Yuanqiang Guo Pharmacometrics 90(5/6): 134-134, 2016. |
New challenge - using prevention, treatment technique development - functional foods of S4-2 dementia 大泉康1,2,3, 木村純子1, 清水広介1, 奥直人1 Pharmacometrics 90(5/6): 135-135, 2016. |
The formulation technology development that we take in the effective ingredient of the formulation technology of S4-3 functional foods, natural product material efficiently and can maintain 嘉島康二 Pharmacometrics 90(5/6): 136-136, 2016. |
Development of S4-4 EPA, DHA functional foods 関口洋一 Pharmacometrics 90(5/6): 137-137, 2016. |
Nicotinic receptor as an S5-1 decision making disorder and the innovative drug development target 溝口博之1, 山田清文2 Pharmacometrics 90(5/6): 138-138, 2016. |
Role of HDAC2 in the nerve mental toxicity with the use of S5-2 antipsychotics chronicity 衣斐大祐1,2, 平松正行1, Gonzalez-Maeso J2 Pharmacometrics 90(5/6): 139-139, 2016. |
Central nerve reproduction mechanism through the S-nitrosylation of the S5-3 epigenome regulatory enzyme 郡山恵樹 Pharmacometrics 90(5/6): 140-140, 2016. |
Development of the amyotrophic lateral sclerosis (ALS) therapeutic drug using the extract derived from S5-4 plant from Okinawa 小菅康弘, 石毛久美子, 伊藤芳久 Pharmacometrics 90(5/6): 141-141, 2016. |
Search of the biomarker about onset weakness of the S6-1 mental disorder 吉見陽1,2, 野田幸裕1, 尾崎紀夫2 Pharmacometrics 90(5/6): 142-142, 2016. |
Pharmacogenomics of the S6-2 psychotropic drug 池田匡志1 Pharmacometrics 90(5/6): 143-143, 2016. |
S6-3 antihistamine and in paired performance 亀井浩行1, 野田幸裕1, 山田清文2, 鍋島俊隆3,4 Pharmacometrics 90(5/6): 144-144, 2016. |
S6-4 psychotropic drug and driving 岩本邦弘 Pharmacometrics 90(5/6): 145-145, 2016. |
Increase inhibition of a culture nervous system trunk, progenitor cells derived from the sea lion dentate gyrus through the Rho signal due to the O1-1 thrombin receptor 田中雅幸, 米山雅紀, 荻田喜代一 Pharmacometrics 90(5/6): 148-148, 2016. |
Analysis - of the Aβ resolution promotion effect using molecular mechanism - pathological model nerve cells of the antidementia effect of the O1-2 Nobile Japanese spaniel 木村純子1, 清水広介1, 嘉島康二2, 横須賀章人3, 三巻祥浩3, 奥直人1, 大泉康1,4,5 Pharmacometrics 90(5/6): 148-148, 2016. |
Effect and the neuroscientific analysis that expression of MHC Class I in the O1-3 astrocyte gives to behavior 祖父江顕1, 伊藤教道1, 羽田和弘1, 中島晶1, 永井拓1, 鍋島俊隆2, 山田清文1 Pharmacometrics 90(5/6): 149-149, 2016. |
Analysis of the gene expression mechanism of O1-4 mental disorder association gene hati/Nat8l 宇野恭介, 宮崎杜夫, 宮本嘉明, 袖山健吾, 新田淳美 Pharmacometrics 90(5/6): 149-149, 2016. |
The O2-1 oxytocin administration improves autism-like behavior by the valproic acid exposure for fetus 松尾和哉, 矢吹悌, 福永浩司 Pharmacometrics 90(5/6): 150-150, 2016. |
Physiological significance of the central histamine nervous system adjustment by O2-2 NPY 梅原隼人, 樋口宗史 Pharmacometrics 90(5/6): 150-150, 2016. |
Anticancer agent-induced neuropathy depressant action of the O2-3 Goshajinkigan 高梨健太1, 柴田圭輔1, 水野景太2, 大宮雄司2, 小泉修一1 Pharmacometrics 90(5/6): 151-151, 2016. |
New treatment development of the O2-4 intractable depression 森口茂樹, 福永浩司 Pharmacometrics 90(5/6): 151-151, 2016. |
Protective efficacy of multiinfarct dementia of the oral O3-1 glutathione administration 福永浩司, 矢吹悌 Pharmacometrics 90(5/6): 152-152, 2016. |
Cholinergic transmission mechanism in the O3-2 center 村松郁延1,2, 吉木はつみ2, 宇和田淳介3, 益岡尚由1, 定清直2, 谷口隆信3, 西尾眞友1 Pharmacometrics 90(5/6): 152-152, 2016. |
Differentiation, the increase of the O3-3 humans mesenchyma system stem cell and examination about the characteristic of immunity 佐藤光利1, 武藤里志2 Pharmacometrics 90(5/6): 153-153, 2016. |
Usefulness as the health food material of the O3-4 Madeira vine (Yunnan sundry medicines) 丸山浩司, 嘉島康二 Pharmacometrics 90(5/6): 153-153, 2016. |
Treatment and palliative care of the LS1 pain 下山理史 Pharmacometrics 90(5/6): 156-156, 2016. |
Clinical application to the hematopoietic stem cell transplantation of the LS2 mesenchyma system stem cell 村田誠 Pharmacometrics 90(5/6): 157-157, 2016. |
Uneasiness-like behavior and remission effect of paroxetine that P01 forebrain-specific cholecystokinin receptor 2 overexpression mouse shows 中村綾乃1, 間宮隆吉1,4, 神田沙也加1, 衣斐大祐1, 唐亜平3, 鍋島俊隆2,4, 平松正行1,4 Pharmacometrics 90(5/6): 160-160, 2016. |
The activation of the P02 accumbens nucleus direct way is involved in risk-oriented behavior choice 王天1, 溝口博之2, 犬束歩3, 片平健太郎4, 疋田貴俊5, 山中章弘3, 山田清文1 Pharmacometrics 90(5/6): 160-160, 2016. |
Role of the dopamine D3 receptor in the social nature behavior disorder to be found in P03 schizophrenia-like model animal 成瀬亮1, 肥田裕丈1, 竹内佐織1, 北垣伸治2, 吉見陽1, 野田幸裕1 Pharmacometrics 90(5/6): 161-161, 2016. |
A functional analysis and drug re-positioning of the Colin transporter in P04 humans melanoma cells 稲津正人1,2), 山中力2) Pharmacometrics 90(5/6): 161-161, 2016. |
The effect that inflammatory mediator of P05 neonate period and the compound load of the abuse drug of the early age period give for mentation 竹内佐織1, 肥田裕丈1, 森健太郎1, 北垣伸治2, 吉見陽1, 野田幸裕1 Pharmacometrics 90(5/6): 162-162, 2016. |
An oxidative stress metabolite in the P06 snail inner hair cells death and gap junctional role 山口太郎, 西山徳人, 藤本頼門, 米山雅紀, 荻田喜代一 Pharmacometrics 90(5/6): 162-162, 2016. |
Role of the glutaminic acid transporter in the mental behavior disorder caused by P07 phencyclidine repetitive administration 内田美月1, 肥田裕丈1, 森健太郎1, 北垣伸治2, 尾崎紀夫3, 田中光一4, 吉見陽1, 野田幸裕1 Pharmacometrics 90(5/6): 163-163, 2016. |
Lipid peroxide 4-hydroxynonenal in the P08 living body deteriorates a hearing ability by the gap junctional rupture of snail lateral walls 米山雅紀, 土屋侑子, 山口太郎, 荻田喜代一 Pharmacometrics 90(5/6): 163-163, 2016. |
Depressant action for the onset of Aβ25-35-induced learning, memory impairment with the single dose of P09 Resveratrol 大美文乃, 野村知弘, 衣斐大祐, 間宮隆吉, 平松正行 Pharmacometrics 90(5/6): 164-164, 2016. |
Control structure of the cytopemphis by P10 IFITM3 伊藤教道1, 永井拓1, 衣斐大祐2, 中島晶3, 鍋島俊隆4, 山田清文1 Pharmacometrics 90(5/6): 164-164, 2016. |
Usefulness of the curcumin as the P11 sensorineural deafness preventive preparation 山田彩加, 山口太郎, 三羽尚子, 米山雅紀, 荻田喜代一 Pharmacometrics 90(5/6): 165-165, 2016. |
Expression of MHCI mRNA change in the cerebral cortex of the neonate period mouse receiving the P12 TLR3 agonist and the hippocampus 羽田和弘1, 伊藤教道1, 祖父江顕1, 鍋島俊隆2, 永井拓1, 山田清文1 Pharmacometrics 90(5/6): 165-165, 2016. |
Participation of calpain in the P13 sound traumatic deafness 増田陽介, 山口太郎, 米山雅紀, 荻田喜代一 Pharmacometrics 90(5/6): 166-166, 2016. |
P14 Clozapine improves cognitive deficits of Disc1 Δ2-3/Δ2-3 mice in a touchscreen-equipped visual discrimination task Bolati Wulaer1, Taku Nagai1, Keisuke Kuroda2, Kozo Kaibuchi2, Toshitaka Nabeshima3, Kiyofumi Yamada1 Pharmacometrics 90(5/6): 166-166, 2016. |
P-15 The activity-dependent transcription factor (Npas4) represses pentylenetetrazole-induced epileptogenesis through Homerla in hippocampus pyramidal neurons. Wei Shan1, Taku Nagai1, Nishio Ito1, Kiyofumi Yamada1 Pharmacometrics 90(5/6): 167-167, 2016. |